内镜下冷冻消融对比根治性肾输尿管切除术治疗上尿路尿路上皮癌
本研究回顾性分析116例新诊断高危上尿路尿路上皮癌患者,其中13例接受内镜下冷冻消融(ECA),103例接受根治性肾输尿管切除术(RNU),经1:4倾向评分匹配后比较生存结局、肾功能和并发症。中位随访约28个月,匹配后两组2年总生存率、无进展生存率和膀胱内无复发生存率无显著差异,RNU后肾功能下降而ECA后未下降。作者认为,与RNU相比,ECA治疗上尿路尿路上皮癌的肿瘤学结局不劣,且肾功能保护更优。
要点
- 匹配后ECA组与RNU组2年总生存率(82% vs 84%)、无进展生存率(73% vs 71%)和膀胱内无复发生存率(81% vs 83%)无显著差异。
- RNU后观察到肾功能下降,而ECA后未观察到肾功能下降。
- ECA组5例(41.7%)报告6例次治疗中出现的不良事件,RNU组17例(35.4%)报告20例次。
核心结论
- 与RNU相比,ECA治疗上尿路尿路上皮癌的肿瘤学结局不劣,且肾功能保护更优。
研究设计与样本
- 回顾性分析2019年3月25日至2021年12月8日新诊断高危上尿路尿路上皮癌患者116例,其中ECA组13例、RNU组103例,分析前采用最近邻法进行1:4倾向评分匹配。
主要发现
- ECA组中位随访28.2个月、RNU组中位随访27.6个月,匹配后2年总生存率ECA组82% vs RNU组84%,无进展生存率73% vs 71%,膀胱内无复发生存率81% vs 83%,均无显著差异。
- RNU后观察到肾功能下降,而ECA后未观察到肾功能下降。
- ECA组5例(41.7%)报告6例次治疗中出现的不良事件,RNU组17例(35.4%)报告20例次治疗中出现的不良事件。
临床怎么用
- 作者认为,对于强烈偏好保留肾脏的特定患者,可考虑ECA这一选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Cryoablation is a traditional antitumor therapy with good prospects for development. The efficacy of endoscopic management as a kidney-sparing surgery for high-risk upper tract urothelial carcinoma (UTUC) remains controversial. Our aim was to evaluate the impact of endoscopic cryoablation (ECA) versus radical nephroureterectomy (RNU) on survival outcomes, renal function, and complications. METHODS: We retrospectively analyzed data for 116 patients with newly diagnosed high-risk UTUC who underwent either ECA (n = 13) or RNU (n = 103) from March 25, 2019 to December 8, 2021. Propensity score matching (1:4) using the nearest neighbor method was performed before analysis. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), intravesical recurrence-free survival (RFS), the change in renal function, and treatment-emergent adverse events (TEAEs). KEY FINDINGS AND LIMITATIONS: At median follow-up of 28.2 mo for the ECA group and 27.6 mo for the RNU group, 2-yr OS (82% vs 84%), PFS (73% vs 71%), and intravesical RFS (81% vs 83%) rates after matching did not significantly differ. A decline in renal function was observed after RNU, but not after ECA. Five (41.7%) patients in the ECA group reported six TEAEs, and 17 patients (35.4%) in the RNU group reported 20 TEAEs. CONCLUSIONS AND CLINICAL IMPLICATIONS: In comparison to RNU, ECA for UTUC resulted in noninferior oncological outcomes and superior preservation of renal function. PATIENT SUMMARY: Our study suggests that a treatment called endoscopic cryoablation for high-risk cancer in the upper urinary tract can help in preserving kidney function, with similar survival outcomes to those after more extensive surgery. This option can be considered for selected patients with a strong preference for kidney preservation.
引用
- Chen Y, Xu C, Mou Z, et al. Endoscopic Cryoablation Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2024. PMID: 38693018. doi:10.1016/j.euo.2024.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。